Luteinizing-Hormone Releasing-Hormone Receptors (LHRH-R) are overexpressed on a variety of reproductive cancers, and can therefore serve as targets for high mortality cancers like Triple Negative Breast Cancer (TNBC) and Ovarian Cancer1,2. Targeting of LHRH-R with agents linked to the natural receptor ligand, the decapeptide Luteinizing-Hormone Releasing-Hormone (LHRH), enables precise targeting of chemotherapeutics and radiometals to tumors bearing LHRH-R. Preclinical evaluations of the cisplatin analog, Pt-Mal-LHRH, has shown encouraging results in targeting and destroying TNBC cancer in murine studies as well as in vitro2. A second series of LHRH bearing agents, 99mTc-acdien-LHRH and 99mTc-Acdien-peg-LHRH, have shown high target fidelities to TNBC cell lines (4T1 and MDA-MB-231 cells) and may prove to be a potent tumor specific radio-imaging agent1. Using these agents, it could be possible to detect and destroy LHRH-R bearing tumors in earlier clinical stages and more effectively. When considered alongside the growing number of peptide drug conjugates (PDCs), a new and hopeful era of cancer treatment can be anticipated, one wherein malignant cells are targeted while neighboring healthy tissues are spared.
Semester/Year of Award
Margaret W. Ndinguri
Mentor Department Affiliation
Restricted Access Thesis
Elliott, Andrew S., "Luteinizing-Hormone Releasing Hormone Directed Cisplatin and 99mTc Imaging Agents, Progress and Future Steps" (2022). Honors Theses. 905.